GlassScriptPhysician profile
Bernadette L Mayers
NPI 1265771406
$6,168.41
in general payments reported to CMS, 2019-2025
21 companies · $2,473 in 2025
The $2,473 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $496 · 2023: $1,377 · 2024: $1,822 · 2025: $2,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,672.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,544.79 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $720.41 | 2024-2025 | |
| Abbvie INC. | $652.72 | 2022-2025 | |
| Alkermes, INC. | $367.56 | 2024-2025 | Lybalvi |
| Neurocrine Biosciences, INC. | $323.73 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $256.34 | 2024-2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.00 | 2024 | |
| Calliditas Therapeutics US INC. | $249.88 | 2023 | Tarpeyo |
| Gilead Sciences, INC. | $246.61 | 2022-2025 | Vemlidy |
| Janssen Pharmaceuticals, INC | $150.00 | 2024 | Invega Trinza, Invega Sustenna |
| Sage Therapeutics, LLC | $146.29 | 2023 | |
| Shield Therapeutics INC | $145.93 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.05 | 2023 | |
| Abbott Laboratories | $138.20 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $125.80 | 2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $125.00 | 2024 | Wegovy |
| Supernus Pharmaceuticals, INC. | $125.00 | 2024 | Qelbree |
| Abiomed | $125.00 | 2025 | |
| Viiv Healthcare Company | $121.92 | 2024 | Dovato |
| Mylan Specialty L.P. | $120.61 | 2023 | Yupelri |
| Impel Pharmaceuticals INC. | $90.57 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Mayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.